Which generation of targeted drugs does sotorasib belong to? Pharmacological mechanisms and therapeutic strategies

Sotorasib (AMG510, Sotorasib) is a targeted drug targeting KRAS G12C mutation. It is an innovative drug in the field of targeted therapy, and its main target, KRAS mutation, was once considered "untargetable". KRAS gene mutations are very common in various malignant tumors such as lung cancer, colon cancer, and pancreatic cancer. Especially in patients with non-small cell lung cancer (NSCLC), about 13% to 15% of cases have KRAS mutations. KRAS mutations often lead to uncontrolled cell signaling and promote tumor growth and metastasis. KRAS G12C mutation is one of the most common types of KRAS mutations. The discovery of this mutation site provides a new breakthrough for targeted therapy.

As the first generationKRAS G12C inhibitor, sotorasiib irreversibly binds to the KRAS G12C mutation site, changes the conformation of KRAS, inhibits the activation of its downstream signaling pathways, thereby blocking the proliferation and survival of tumor cells. Specifically, the KRAS G12C mutation keeps the KRAS protein in a continuously "active" state, driving cell proliferation and tumor growth. Sotoracib binds to the mutated KRAS G12C protein, inhibits its activity, and reduces tumor cells' dependence on growth factors, thereby controlling tumor growth.

This drug has a unique pharmacological mechanism and belongs to an emerging class of targeted drugs. The efficacy of sotoracib has been verified in clinical trials, especially in patients with KRAS G12C mutant non-small cell lung cancer (NSCLC), which showed significant anti-tumor effects. In a clinical study called CodeBreaK 100, sotoraxib demonstrated promising therapeutic effects in patients with KRAS G12C mutated advanced non-small cell lung cancer. This study shows that sotorasib can significantly improve the progression-free survival (PFS) and objective response rate (ORR) of patients, and is generally well tolerated with relatively mild side effects.

Reference materials:https://www.lumakras.com/